Literature DB >> 9809823

Neurological outcome in adult patients with early-treated phenylketonuria.

J Pietz1, R Dunckelmann, A Rupp, D Rating, H M Meinck, H Schmidt, H J Bremer.   

Abstract

UNLABELLED: Due to the observation of severe neurological symptoms in single patients as well as brain imaging, neuropsychological and neurophysiological abnormalities, the long-term prognosis of treated phenylketonuria is still under discussion. We investigated the neurological outcome of 57 (24 male, 33 female) patients with phenylketonuria (diet onset < 3 months) at a mean age of 23.6 (17-33) years in comparison to control subjects. Methods used were a clinical-neurological examination, tests for fine motor abilities, IQ test (WAIS-R), a neuropsychological attention task and MRI (30 patients only). Tremor was increased in the patients (28%) compared to controls (15%). Fine motor abilities were significantly reduced in three areas: hand-wrist steadiness, finger-hand dexterity and hand-wrist speed. Tremor as well as reduced fine motor skills were not associated with treatment-related variables, e.g. diet onset, strictness of biochemical control or amount of MRI white matter change. IQ was lower in patients (mean 97.6) compared to matched control subjects (mean 105.5). IQ at 12 years was correlated with biochemical control from birth up to the age of 12 and remained stable up to adult age, independent of biochemical control after 12 years of age. In contrast to the other outcome parameters, the performance in a neuropsychological attention task was influenced by the concurrent plasma phenylalanine concentration. Specific late-onset neurological impairment was not identified in this sample of early-treated adults with phenylketonuria.
CONCLUSION: Careful neurological investigation revealed subtle symptoms of brain damage even after early-initiated treatment in adult patients with phenylketonuria. At present it cannot be excluded that further neurological deterioration could emerge later in life. Thus, patients with phenylketonuria - either on or off diet - should be monitored throughout life.

Entities:  

Mesh:

Year:  1998        PMID: 9809823     DOI: 10.1007/s004310050945

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  25 in total

1.  Measurement of neurotransmitter metabolites in the cerebrospinal fluid of phenylketonuric patients under dietary treatment.

Authors:  A B Burlina; L Bonafé; V Ferrari; A Suppiej; F Zacchello; A P Burlina
Journal:  J Inherit Metab Dis       Date:  2000-06       Impact factor: 4.982

2.  PKU is a reversible neurodegenerative process within the nigrostriatum that begins as early as 4 weeks of age in Pah(enu2) mice.

Authors:  Jennifer E Embury; Catherine E Charron; Anatoly Martynyuk; Andreas G Zori; Bin Liu; Syed F Ali; Neil E Rowland; Philip J Laipis
Journal:  Brain Res       Date:  2006-11-15       Impact factor: 3.252

3.  Characterization of tremor in phenylketonuric patients.

Authors:  Belén Pérez-Dueñas; Josep Valls-Solé; Emilio Fernández-Alvarez; Jaon Conill; Maria Antonio Vilaseca; Rafael Artuch; Jaume Campistol
Journal:  J Neurol       Date:  2005-07-05       Impact factor: 4.849

4.  Tetrahydrobiopterin (BH4) in PKU: effect on dietary treatment, metabolic control, and quality of life.

Authors:  B Ziesch; J Weigel; A Thiele; U Mütze; C Rohde; U Ceglarek; J Thiery; W Kiess; S Beblo
Journal:  J Inherit Metab Dis       Date:  2012-03-06       Impact factor: 4.982

5.  Neuropsychological outcome of subjects participating in the PKU adult collaborative study: a preliminary review.

Authors:  V L Brumm; C Azen; R A Moats; A M Stern; C Broomand; M D Nelson; R Koch
Journal:  J Inherit Metab Dis       Date:  2004       Impact factor: 4.982

6.  Large neutral amino acids in the treatment of phenylketonuria (PKU).

Authors:  R Matalon; K Michals-Matalon; G Bhatia; E Grechanina; P Novikov; J D McDonald; J Grady; S K Tyring; F Guttler
Journal:  J Inherit Metab Dis       Date:  2006-09-21       Impact factor: 4.982

7.  Plasma phenylalanine is associated with decreased serum ubiquinone-10 concentrations in phenylketonuria.

Authors:  R Artuch; C Colomé; M A Vilaseca; C Sierra; F J Cambra; N Lambruschini; J Campistol
Journal:  J Inherit Metab Dis       Date:  2001-06       Impact factor: 4.982

8.  Assessment of mitochondrial respiratory chain function in hyperphenylalaninaemia.

Authors:  N Kyprianou; E Murphy; P Lee; I Hargreaves
Journal:  J Inherit Metab Dis       Date:  2009-03-13       Impact factor: 4.982

Review 9.  The truth of treating patients with phenylketonuria after childhood: the need for a new guideline.

Authors:  F J van Spronsen; P Burgard
Journal:  J Inherit Metab Dis       Date:  2008-08-12       Impact factor: 4.982

Review 10.  Large neutral amino acids supplementation in phenylketonuric patients.

Authors:  J C Rocha; F Martel
Journal:  J Inherit Metab Dis       Date:  2009-05-13       Impact factor: 4.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.